Categories
Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-25)

In this article we will discuss Durvalumab (Warnings-25)

In this article, we will discuss Durvalumab (Warnings-25). So, let’s get started.

Immune-Mediated Nephritis with Renal Dysfunction: Durvalumab can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.5% (10/1889) of patients receiving Durvalumab, including Grade 3 (<0.1%) adverse reactions. Events resolved in 5 of the 10 patients and resulted in permanent discontinuation in 3 patients. Systemic corticosteroids were required in all patients with immune-mediated nephritis.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Discover more from PT Master Guide

Subscribe now to keep reading and get access to the full archive.

Continue reading